Sort   by:  
 Page size 
ProteomicsInvestigating the target and off-target landscape of PLK1 small molecule inhibitor volasertib
In this study we aimed to identify off-targets of polo-like kinase 1 (Plk1) small molecule inhibitor volasertib. Plk1 is an important cell cycle kinase and an attractive target for anticancer treatment. Volasertib is ATP-competitive small molecules that may also block the ATP-pocket of other protein...
ORGANISM(S): Homo sapiens (Human) 
2021-08-23 | PXD024040 | Pride
Volasertib Lc-ms Leukemia Plk1 
ProteomicsInvestigating the target and off-target landscape of PLK1 small molecule inhibitor volasertib
In this study we aimed to identify off-targets of polo-like kinase 1 (Plk1) small molecule inhibitor volasertib. Plk1 is an important cell cycle kinase and an attractive target for anticancer treatment. Volasertib is ATP-competitive small molecules that may also block the ATP-pocket of other protein...
ORGANISM(S): Homo sapiens (Human) 
2021-08-23 | PXD023757 | Pride
Drug Tpp Lc-ms Leukemia 
UnknownIdentification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.
Not available
S-EPMC5667974 | biostudies-literature
UnknownVolasertib preclinical activity in high-risk hepatoblastoma.
Not available
S-EPMC6849653 | biostudies-literature
GenomicsOnly infant MLL rearranged leukemia is susceptible to an inhibition of PLK-1 by volasertib
Only infant MLL rearranged leukemia is susceptible to an inhibition of PLK-1 by volasertib
PRJNA1158260 | ENA
UnknownDiscovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
Not available
S-EPMC4335352 | biostudies-literature
TranscriptomicsOnly infant MLL rearranged leukemia is susceptible to an inhibition of PLK-1 by volasertib
MLL rearranged (MLLr) leukemia is in general characterized by a poor prognosis. Depending on the cell of origin, it can differ in the aggressiveness and the therapy response. For instance, in adults, volasertib blocking Polo-like-Kinase 1 (PLK-1), was well-tolerated, but only with limited success. O...
ORGANISM(S): Homo sapiens 
2024-12-19 | GSE276639 | GEO
UnknownThe polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
Not available
S-EPMC5828226 | biostudies-literature
TranscriptomicsSynergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
Interactions between a new potent Bromodomain and extraterminal domain (BET) inhibitor BI 894999 and the polo-like kinase (PLK) inhibitor volasertib were studied in acute myeloid leukemia cell lines in vitro and in vivo. We provide data for the distinct mechanisms of action of these two compounds wi...
ORGANISM(S): Homo sapiens 
2018-02-27 | GSE103068 | GEO
UnknownPhase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
Not available
S-EPMC4714695 | biostudies-literature
Sort   by:  
 Page size